Quinoxaline 1,4-di-N-Oxide Derivatives: Are They Unselective or SelectiveInhibitors? / Gildardo Rivera
Background: For decades, the quinoxaline 1,4-di-N-oxide ring has been considered a privileged structureto develop new antibacterial, antitumoural, and antiprotozoal agents, among others; however, itsmechanism of action is not clear. Objective: The main aim of this mini-review was to analyze the mechanism of action of quinoxaline1,4-di-N-oxide derivatives reported as antibacterial, antitumoural, and antiprotozoal agents. Results: Initially, the mechanism of action of quinoxaline 1,4-di-N-oxide derivatives against bacteria,tumoural cell lines, and parasites have been described as nonspecific, but recently, the results againstdifferent organisms have shown that these compounds have an inhibitory action on specific targetssuch as trypanothione reductase, triosephosphate isomerase, and other essential enzymes. Conclusion: In summary, quinoxaline 1,4-di-N-oxide is a scaffold to develop new anti- Mycobacterium tuberculosis , antitumoural and antiprotozoal agents; however, understanding themechanism of action of quinoxaline 1,4-di-N-oxide derivatives in each microorganism could contributeto the development of new and more potent selective drugs.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:22 |
|---|---|
| Enthalten in: |
Mini-reviews in ... medicinal chemistry - 22(2022), 1, Seite 11 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Rivera, Gildardo [VerfasserIn] |
|---|
| Links: |
FID Access [lizenzpflichtig] |
|---|
| Umfang: |
1 Online-Ressource (11 p) |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
KFL011180048 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | KFL011180048 | ||
| 003 | DE-627 | ||
| 005 | 20231128075956.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230613s2022 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)KFL011180048 | ||
| 035 | |a (KFL)prod_DARH_.54FF919F844D8A07D7E27796B7CE84C02B6584B1 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 084 | |a PHARM |q DE-84 |2 fid | ||
| 100 | 1 | |a Rivera, Gildardo |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Quinoxaline 1,4-di-N-Oxide Derivatives: Are They Unselective or SelectiveInhibitors? |c Gildardo Rivera |
| 264 | 1 | |c 2022 | |
| 300 | |a 1 Online-Ressource (11 p) | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Background: For decades, the quinoxaline 1,4-di-N-oxide ring has been considered a privileged structureto develop new antibacterial, antitumoural, and antiprotozoal agents, among others; however, itsmechanism of action is not clear. Objective: The main aim of this mini-review was to analyze the mechanism of action of quinoxaline1,4-di-N-oxide derivatives reported as antibacterial, antitumoural, and antiprotozoal agents. Results: Initially, the mechanism of action of quinoxaline 1,4-di-N-oxide derivatives against bacteria,tumoural cell lines, and parasites have been described as nonspecific, but recently, the results againstdifferent organisms have shown that these compounds have an inhibitory action on specific targetssuch as trypanothione reductase, triosephosphate isomerase, and other essential enzymes. Conclusion: In summary, quinoxaline 1,4-di-N-oxide is a scaffold to develop new anti- Mycobacterium tuberculosis , antitumoural and antiprotozoal agents; however, understanding themechanism of action of quinoxaline 1,4-di-N-oxide derivatives in each microorganism could contributeto the development of new and more potent selective drugs | ||
| 773 | 0 | 8 | |i Enthalten in |t Mini-reviews in ... medicinal chemistry |d Hilversum, the Netherlands [u.a.] : Bentham Science Publ., 2001 |g 22(2022), 1, Seite 11 |h Online-Ressource |w (DE-627)KFL000006394 |w (DE-600)2104083-7 |w (DE-576)273887203 |x 1875-5607 |7 nnns |
| 773 | 1 | 8 | |g volume:22 |g year:2022 |g number:1 |g pages:11 |
| 856 | 4 | 0 | |u http://pharmazie.proxy.fid-lizenzen.de/fid/bentham-ejournals-pharmazie/www.eurekaselect.com/openurl/content.php?genre=article&issn=1389-5575&volume=22&issue=1&spage=15 |m X:KFL |x Verlag |y FID Access |z lizenzpflichtig |
| 912 | |a ZDB-1-BEJ | ||
| 912 | |a GBV_KFL | ||
| 912 | |a FID-PHARM | ||
| 935 | |i IMPORT_0628_prod_DARH_03 | ||
| 951 | |a AR | ||
| 952 | |d 22 |j 2022 |e 1 |h 11 | ||